Joan Sellers

Keine laufenden Positionen mehr

Commercial Services

Consumer Services

Health Technology

Ehemalige bekannte Positionen von Joan Sellers

Unternehmen	Position	Beginn	Ende
Targeted Cell Therapies LLC	Corporate Officer/Principal	01.01.2010	01.01.2010
Vasculogic LLC	Gründer	01.01.2006	01.01.2006
Vasculogic LLC	Präsident	-	01.01.2006
Transkaryotic Therapies, Inc. Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.	Corporate Officer/Principal	01.01.1994	01.01.1994
NANOMIX CORPORATION	Technik-/Wissenschafts-/F&E-Leiter	06.04.2011	-

State University of New York at Albany

Doctorate Degree

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Founder	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Private Unternehmen	4
Transkaryotic Therapies, Inc. Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.	Commercial Services
Targeted Cell Therapies LLC
Boston Therapeutics, Inc. Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA.	Health Technology
Vasculogic LLC